Quantcast

Latest Heparin Stories

2009-11-18 10:54:00

NEW YORK, Nov. 18 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Anticoagulants - A Global Market Review http://www.reportlinker.com/p0164225/Anticoagulants---A-Global-Market-Review.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire The world anticoagulants market is driven by patent expiries, development of novel therapeutics, and rapidly aging population. With just two therapy classes - vitamin K...

2009-11-17 15:25:00

SAN FRANCISCO, Nov. 17 /PRNewswire-FirstCall/ -- Merriman Curhan Ford Group, Inc. (Nasdaq: MERR) acted as lead placement agent in PolyMedix Inc.'s (OTC Bulletin Board: PYMX) $20.7 million registered public offering of 20.7 million units. The units, which were priced at $1.00 per unit, consist of one share of PolyMedix common stock and one five year warrant to purchase 0.30 of a share of PolyMedix common stock at $1.25 per share. (Logo: http://www.newscom.com/cgi-bin/prnh/20090911/MCFLOGO)...

2009-10-12 18:28:22

An outbreak of bloodstream infections appears to have been caused by the contamination of pre-filled heparin and saline syringes made by a single company, according to a report in the October 12 issue of Archives of Internal Medicine, one of the JAMA/Archives journals. The subsequent investigation revealed that the company was not in compliance with safety regulations and identified challenges and areas for improvement in medication monitoring systems. Between October 2007 and February 2008,...

2009-10-01 12:55:47

The U.S. Food and Drug Administration says a change in heparin manufacturing controls will reduce the blood-thinning drug's potency. To ensure the quality of heparin and to guard against potential contamination, the United States Pharmacopeia -- a non-profit standards-setting organization -- adopted new manufacturing controls for heparin, the FDA said in a statement. These changes include a modification of the reference standard for the drug's unit dose. In an alert issued to healthcare...

2009-10-01 12:25:00

Adjustments may be needed to achieve desired anticoagulant effect in some patients New Heparin to Ship Starting October 8 SILVER SPRING, Md., Oct. 1 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today alerted health care professionals to a change in heparin manufacturing that is expected to decrease the potency of the common blood-clotting drug. (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO) To ensure the quality of heparin and to guard against...

2009-10-01 06:30:00

WESTPORT, Conn., Oct. 1 /PRNewswire/ -- Dr. Mark Wurster from The Ohio State University Medical Center presented his findings at the September 29th meeting of the University Health Consortium's Fall Forum. According to Dr. Wurster, "OSU is the only organization out of 31 participants in the UHC benchmarking study that qualified for better performance status. OSUMC showed excellent results and achieved above the UHC mean in every area of managing anticoagulation therapy with the use of...

2009-09-28 15:15:31

Heparin, a commonly used anticoagulant, can cause skin lesions, reports a study in CMAJ (Canadian Medical Association Journal). Skin lesions caused by heparin may indicate the presence of a life-threatening decrease in the number of platelets, a condition called "heparin-induced thrombocytopenia" or a, in most cases self-limiting, allergic skin reaction. The study looked at 320 patients undergoing heparin injections over 12 months at The Hospital of The Johann Wolfgang Goethe University in...

2009-09-09 07:30:00

BASKING RIDGE, N.J., Sept. 9 /PRNewswire/ -- Regado Biosciences, a privately held company leading the development of antithrombotic therapeutic aptamers with active control agents, announced that on September 8, 2009 enrollment of the first patient in a Phase 2b, randomized, partially-blinded, multi-center, active-controlled, dose-ranging study of its lead product candidate, the REG1 anticoagulation system (REG1) was achieved. REG1 comprises the selective factor IXa inhibitor, RB006, and...

2009-08-31 15:45:00

LAKE FOREST, Ill., Aug. 31 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, today announced that the U.S. Food and Drug Administration (FDA) has approved the company's applications for six new presentations of therapeutic heparin in single- and multiple-dose vials. Heparin is used to prevent clot formation in central venous catheters and for anticoagulant (blood thinning) therapy, and is available in numerous delivery systems for...

2009-08-31 08:43:55

Data from a phase II trial of an investigational intravenous drug designed to block the formation of blood clots shows potential to reduce the risk of death, a second heart attack, or other coronary complications compared with the current standard of care in patients presenting with acute coronary syndromes (heart attacks or unstable angina).Otamixaban inhibits the activity of Factor Xa, a key enzyme involved in the process of blood coagulation. It has already shown promising results when...


Word of the Day
negawatt
  • A unit of saved energy.
Coined by Amory Lovins, chairman of the Rocky Mountain Institute as a contraction of negative watt on the model of similar compounds like megawatt.